A novel prognostic model based on four circulating miRNA in diffuse large B‐cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression
MicroRNA (miRNA) have been emerged as prognostic biomarkers in diffuse large B‐cell lymphoma (DLBCL). To understand the potential underlying mechanisms and translate these findings into clinical prediction on lymphoma progression, large patient cohorts should be evaluated. Here, using miRNA PCR arra...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12834 |
_version_ | 1818904416373178368 |
---|---|
author | Rui Sun Zhong Zheng Li Wang Shu Cheng Qing Shi Bin Qu Di Fu Christophe Leboeuf Yan Zhao Jing Ye Anne Janin Wei‐Li Zhao |
author_facet | Rui Sun Zhong Zheng Li Wang Shu Cheng Qing Shi Bin Qu Di Fu Christophe Leboeuf Yan Zhao Jing Ye Anne Janin Wei‐Li Zhao |
author_sort | Rui Sun |
collection | DOAJ |
description | MicroRNA (miRNA) have been emerged as prognostic biomarkers in diffuse large B‐cell lymphoma (DLBCL). To understand the potential underlying mechanisms and translate these findings into clinical prediction on lymphoma progression, large patient cohorts should be evaluated. Here, using miRNA PCR array, we analyzed the miRNA expression profiles in serum samples of 20 DLBCL patients at diagnosis, remission and relapse. Four candidate miRNA were identified and subsequently evaluated for their ability to predict relapse and survival. A prognostic model based on four circulating miRNA (miR21, miR130b, miR155 and miR28) was established and tested in a training cohort of 279 patients and in a validation cohort of 225 patients (NCT01852435). The prognostic value of the 4‐circulating miRNA model was assessed by univariate and multivariate analyses. The novel 4‐circulating miRNA prognostic model significantly predicted clinical outcome of DLBCL, independent of International Prognostic Index in the training cohort [hazard ratio (HR) = 2.83, 95% CI 2.14–3.51, P < 0.001] and in the validation cohort (HR = 2.71, 95% CI 1.91–3.50, P < 0.001). Moreover, DNA‐ and RNA‐sequencing was performed on tumor samples to detect genetic mutations and signaling pathway dysregulation. DNA‐sequencing data showed no significant difference of tumor mutation burden between the low‐risk and the high‐risk groups of the 4‐circulating miRNA model. RNA‐sequencing revealed a correlation between the 4‐circulating miRNA model and aberrant Ras protein signaling transduction. The impact of the miRNA signature on oncogenic signaling and tumor microenvironment was analyzed in vitro and in vivo. In B‐lymphoma cells, modulation of the miRNA regulated IGF1 and JUN expression, thereby altering MDSC and Th17 cells. In DLBCL patients, the high‐risk group presented Ras signaling activation, increased MDSC and Th17 cells, and immunosuppressive status compared with the low‐risk group. In conclusion, the easy‐to‐use 4‐circulating miRNA prognostic model effectively predicted relapse and survival in DLBCL. Moreover, the tumor microenvironment contributes to the role of the 4‐circulating miRNA model in DLBCL progression. |
first_indexed | 2024-12-19T21:07:05Z |
format | Article |
id | doaj.art-beb4dab283e94096b22464de9a7d7795 |
institution | Directory Open Access Journal |
issn | 1574-7891 1878-0261 |
language | English |
last_indexed | 2024-12-19T21:07:05Z |
publishDate | 2021-01-01 |
publisher | Wiley |
record_format | Article |
series | Molecular Oncology |
spelling | doaj.art-beb4dab283e94096b22464de9a7d77952022-12-21T20:05:36ZengWileyMolecular Oncology1574-78911878-02612021-01-0115124626110.1002/1878-0261.12834A novel prognostic model based on four circulating miRNA in diffuse large B‐cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progressionRui Sun0Zhong Zheng1Li Wang2Shu Cheng3Qing Shi4Bin Qu5Di Fu6Christophe Leboeuf7Yan Zhao8Jing Ye9Anne Janin10Wei‐Li Zhao11Shanghai Institute of Hematology State Key Laboratory of Medical Genomics National Research Center for Translational Medicine at ShanghaiRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ChinaShanghai Institute of Hematology State Key Laboratory of Medical Genomics National Research Center for Translational Medicine at ShanghaiRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ChinaShanghai Institute of Hematology State Key Laboratory of Medical Genomics National Research Center for Translational Medicine at ShanghaiRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ChinaShanghai Institute of Hematology State Key Laboratory of Medical Genomics National Research Center for Translational Medicine at ShanghaiRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ChinaShanghai Institute of Hematology State Key Laboratory of Medical Genomics National Research Center for Translational Medicine at ShanghaiRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ChinaDepartment of Laboratory Medicine Shanghai Rui Jin HospitalShanghai Jiao Tong University School of Medicine ChinaShanghai Institute of Hematology State Key Laboratory of Medical Genomics National Research Center for Translational Medicine at ShanghaiRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ChinaU1165 Inserm/Université Paris 7Hôpital Saint Louis Paris FranceShanghai Institute of Hematology State Key Laboratory of Medical Genomics National Research Center for Translational Medicine at ShanghaiRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ChinaLaboratory of Molecular Pathology Pôle de Recherches Sino‐Français en Science du Vivant et Génomique Shanghai ChinaU1165 Inserm/Université Paris 7Hôpital Saint Louis Paris FranceShanghai Institute of Hematology State Key Laboratory of Medical Genomics National Research Center for Translational Medicine at ShanghaiRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine ChinaMicroRNA (miRNA) have been emerged as prognostic biomarkers in diffuse large B‐cell lymphoma (DLBCL). To understand the potential underlying mechanisms and translate these findings into clinical prediction on lymphoma progression, large patient cohorts should be evaluated. Here, using miRNA PCR array, we analyzed the miRNA expression profiles in serum samples of 20 DLBCL patients at diagnosis, remission and relapse. Four candidate miRNA were identified and subsequently evaluated for their ability to predict relapse and survival. A prognostic model based on four circulating miRNA (miR21, miR130b, miR155 and miR28) was established and tested in a training cohort of 279 patients and in a validation cohort of 225 patients (NCT01852435). The prognostic value of the 4‐circulating miRNA model was assessed by univariate and multivariate analyses. The novel 4‐circulating miRNA prognostic model significantly predicted clinical outcome of DLBCL, independent of International Prognostic Index in the training cohort [hazard ratio (HR) = 2.83, 95% CI 2.14–3.51, P < 0.001] and in the validation cohort (HR = 2.71, 95% CI 1.91–3.50, P < 0.001). Moreover, DNA‐ and RNA‐sequencing was performed on tumor samples to detect genetic mutations and signaling pathway dysregulation. DNA‐sequencing data showed no significant difference of tumor mutation burden between the low‐risk and the high‐risk groups of the 4‐circulating miRNA model. RNA‐sequencing revealed a correlation between the 4‐circulating miRNA model and aberrant Ras protein signaling transduction. The impact of the miRNA signature on oncogenic signaling and tumor microenvironment was analyzed in vitro and in vivo. In B‐lymphoma cells, modulation of the miRNA regulated IGF1 and JUN expression, thereby altering MDSC and Th17 cells. In DLBCL patients, the high‐risk group presented Ras signaling activation, increased MDSC and Th17 cells, and immunosuppressive status compared with the low‐risk group. In conclusion, the easy‐to‐use 4‐circulating miRNA prognostic model effectively predicted relapse and survival in DLBCL. Moreover, the tumor microenvironment contributes to the role of the 4‐circulating miRNA model in DLBCL progression.https://doi.org/10.1002/1878-0261.12834diffuse large B‐cell lymphomamicroRNAprognosisRas protein signal transductiontumor microenvironment |
spellingShingle | Rui Sun Zhong Zheng Li Wang Shu Cheng Qing Shi Bin Qu Di Fu Christophe Leboeuf Yan Zhao Jing Ye Anne Janin Wei‐Li Zhao A novel prognostic model based on four circulating miRNA in diffuse large B‐cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression Molecular Oncology diffuse large B‐cell lymphoma microRNA prognosis Ras protein signal transduction tumor microenvironment |
title | A novel prognostic model based on four circulating miRNA in diffuse large B‐cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression |
title_full | A novel prognostic model based on four circulating miRNA in diffuse large B‐cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression |
title_fullStr | A novel prognostic model based on four circulating miRNA in diffuse large B‐cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression |
title_full_unstemmed | A novel prognostic model based on four circulating miRNA in diffuse large B‐cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression |
title_short | A novel prognostic model based on four circulating miRNA in diffuse large B‐cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression |
title_sort | novel prognostic model based on four circulating mirna in diffuse large b cell lymphoma implications for the roles of mdsc and th17 cells in lymphoma progression |
topic | diffuse large B‐cell lymphoma microRNA prognosis Ras protein signal transduction tumor microenvironment |
url | https://doi.org/10.1002/1878-0261.12834 |
work_keys_str_mv | AT ruisun anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT zhongzheng anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT liwang anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT shucheng anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT qingshi anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT binqu anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT difu anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT christopheleboeuf anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT yanzhao anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT jingye anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT annejanin anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT weilizhao anovelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT ruisun novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT zhongzheng novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT liwang novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT shucheng novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT qingshi novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT binqu novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT difu novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT christopheleboeuf novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT yanzhao novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT jingye novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT annejanin novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression AT weilizhao novelprognosticmodelbasedonfourcirculatingmirnaindiffuselargebcelllymphomaimplicationsfortherolesofmdscandth17cellsinlymphomaprogression |